RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants -- Phase 2/3 study s...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107
- The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalization - the vast majority of patients - RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in...
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C., Jan. 28, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of ...
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. clinical sites RHB-...
